Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fostamatinib Disodium Clear all
Enrolling by invitation Phase 3 Interventional

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

NCT04138927
View directory record Official record
Conditions
Warm Antibody Autoimmune Hemolytic Anemia
Interventions
Fostamatinib disodium
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Torrance, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)

NCT02612558
View directory record Official record
Conditions
Warm Antibody Autoimmune Hemolytic Anemia
Interventions
Fostamatinib 150 mg bid
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
31
States / cities
Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

NCT02077192
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
Fostamatinib Disodium
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
9
States / cities
Tucson, Arizona • Peoria, Illinois • Lafayette, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 17, 2026, 10:45 AM EDT
Terminated Phase 2 Interventional Results available

Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study

NCT02092961
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib, Adalimumab, Placebo of Fostamatinib, Placebo of Adalimumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Glendale, Arizona • Paradise Valley, Arizona • Phoenix, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Drug-drug Interaction Between FosD and Verapamil When Taken Together in Healthy Volunteers

NCT01197781
View directory record Official record
Conditions
Drug Drug Interactions, Healthy Volunteers
Interventions
FOSTAMATIN, Verapamil
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2010 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist

NCT01197755
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
fostamatinib, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
67
States / cities
Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 64 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function

NCT01222455
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers, Pharmacokinetics, Amount of R406 in Blood
Interventions
Fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 6, 2011 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects

NCT01167868
View directory record Official record
Conditions
Healthy
Interventions
FosD, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 3 Interventional

Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

NCT04629703
View directory record Official record
Conditions
Covid19, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Pneumonia, Pneumonia, Viral
Interventions
Fostamatinib, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Orange, California • Washington D.C., District of Columbia • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.

NCT01197534
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
fostamatinib, placebo, fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
913 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
57
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

NCT03764618
View directory record Official record
Conditions
Warm Antibody Autoimmune Hemolytic Anemia
Interventions
Fostamatinib disodium, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
26
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma

NCT00798096
View directory record Official record
Conditions
T Cell Lymphoma
Interventions
Fostamatinib Disodium
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
San Francisco, California • Stanford, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...

NCT00923481
View directory record Official record
Conditions
Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
Interventions
Fostamatinib disodium
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis

NCT00665925
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib disodium (R935788), Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
24
States / cities
La Jolla, California • Palm Desert, California • Hamden, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2016 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)

NCT00665626
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib disodium (R935788), Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
27
States / cities
Aventura, California • Palm Desert, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)

NCT00706342
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
Fostamatinib Disodium / R935788
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 17, 2026, 10:45 AM EDT
Terminated Phase 3 Interventional Results available

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

NCT01242514
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,917 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
116
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 113 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2014 · Synced Oct 17, 2026, 10:45 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

NCT01264770
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib and placebo injections, Adalimumab and placebo of fostamatinib, Placebo of fostamatinib, fostamatinib, and placebo injections
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Oct 17, 2026, 10:45 AM EDT
Terminated No phase listed Observational

Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

NCT04904276
View directory record Official record
Conditions
ITP, Immune Thrombocytopenia
Interventions
Fostamatinib
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Tamarac, Florida • Springfield, Illinois • Kansas City, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

NCT02076412
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
Fostamatinib Disodium, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Nyack, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

NCT02076399
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
Fostamatinib disodium, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Lakeland, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 17, 2026, 10:45 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.

NCT01197521
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
fostamatinib, placebo, fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
923 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
41
States / cities
Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Oct 17, 2026, 10:45 AM EDT
Terminated Phase 2 Interventional Results available

Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies

NCT00805467
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib Disodium (R935788)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
35
States / cities
La Jolla, California • Palm Desert, California • Palo Alto, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 17, 2026, 10:45 AM EDT